ZOVIRAX (acyclovir) by Bausch + Lomb is dna polymerase inhibitors [moa]. Approved for herpes simplex virus nucleoside analog dna polymerase inhibitor [epc]. First approved in 2002.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
ZOVIRAX (acyclovir) is a topical cream formulation of a nucleoside analog DNA polymerase inhibitor indicated for herpes simplex virus infection. It works by inhibiting viral DNA replication, preventing viral spread and reducing symptom severity. This is a mature, well-established antiviral with decades of clinical use.
Product is approaching loss of exclusivity with moderate competitive pressure (60/100), suggesting a consolidating team and transition focus toward generic optimization or line extension strategies.
DNA Polymerase Inhibitors
Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
The Bioequivalence Study of Acyclovir 800 mg Tablet in Healthy Thai Volunteers Under Fasting Conditions
Neonatal Phase 1 Valacyclovir Study
A Study to Compare Sitavig (Acyclovir) Buccal Tablet With a Placebo in the Treatment of Herpes Labialis in Participants Whose Immune System Works Normally
Pharmacokinetic Properties of 200 and 400 mg Acyclovir Tablet in Indonesia Healthy Subject
Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyclovir and Interferon Inducer Kagocel
Worked on ZOVIRAX at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on ZOVIRAX offers stability in a mature, well-understood franchise but limited growth opportunity; career trajectory is likely horizontal or involves transition planning as the product approaches LOE. Roles emphasize operational excellence, generic competition management, and strategic portfolio planning rather than launch excitement or clinical expansion.